SCHEMBL791534

SCHEMBL791534

CC(=O)N1CC(=O)NC(=O)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.50
NOTUM Q6P988 2/20 0.46
TOP2A P11388 3/20 0.44
TOP2B Q02880 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
CRBN Q96SW2 2/20 0.42
TSHR P16473 1/20 0.39
CHRNB2 P17787 3/20 0.38
CHRNA3 P32297 3/20 0.38
CHRNA4 P43681 3/20 0.38
CHRNB3 Q05901 1/20 0.38
CHRNA6 Q15825 1/20 0.38
CYP1A2 P05177 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CHRNB4 P30926 2/20 0.37
PTGS1 P23219 2/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18216643 0.76 KMT2A (0.42) PKMNOTUMTOP2ATOP2BTDP1
SCHEMBL3912317 0.76 NOTUM (0.52) NOTUMTDP1ALDH1A1CHRNB2CHRNA3
SCHEMBL6840184 0.76
SCHEMBL31053606 0.75 PKM (0.46) PKMTOP2ATOP2BTDP1ALDH1A1
SCHEMBL6063987 0.73 CRBN (0.46) PKMNOTUMTOP2ATOP2BTDP1
SCHEMBL3907606 0.73 KMT2A (0.56) NOTUMTOP2ATOP2BTDP1ALDH1A1
SCHEMBL1583808 0.72 CYP1A2 (0.47) PKMTDP1ALDH1A1MAPTTSHR
SCHEMBL18587344 0.70
SCHEMBL10143995 0.70 NOTUM (0.52) NOTUMTDP1ALDH1A1CHRNB2CHRNA3
SCHEMBL20517758 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2863916-B1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
US-9376418-B2 Substituted pyridine spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-28 US disclosed
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK CANADA INC. (CA) 2015-05-28 US disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
EP-1790636-A1 PIPERIDINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-05-30 EP disclosed
US-4523013-A 4-Acyl-2,6-dioxo-1-phenethyl piperozines SANOFI, S.A. (FR) 1985-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PKM 4270/4885NOTUM 548/4885TOP2A 1732/4885
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS SYK, BTK, LYN PKM 659/4885NOTUM 4022/4885TOP2A 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.